Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality
Open Access
- 22 August 2023
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 7 (6) , 1007-1013
Abstract
Introduction This review aims to critically appraise differences in methodology and quality of model-based and empirical-data-based cost-utility studies to address key limitations, opportunities, and challenges to inform future cost-utility analyses of continuous glucose monitoring (CGM) in type 1 diabetes. This protocol is registered at PROSPERO (CRD42023391284). Methods The review will be conducted in accordance with the PRISMA guideline for systematic reviews. Searches will be conducted in MEDLINE, Embase, Web of Science, Cochrane Library, and Econlit from 2000 to January 2023. Model and empirical data-based studies evaluating the cost-utility of any CGM system in type 1 diabetes will be considered for inclusion. Studies that only report on cost per life year or any other clinical outcome, or reporting only costs or only clinical outcomes studies in type 2 diabetes populations, and studies on bi-hormonal closed loops and do-it-yourself hybrid closed loop devices will be excluded. Two reviewers will independently screen each study for inclusion. Data on the intervention, population, model settings (such as perspective, time horizon), model type and structure, clinical outcomes used to populate the model, validation, and uncertainty will be extracted and qualitatively synthesised. Quality will be assessed using the Philips et al. 2006 (model-based studies) or Consensus Health Economic Criteria (empirical data-based studies) checklists. Model validation will be assessed using the AdViSHE checklist. Discussion Now that CGM is being used more broadly in practice, critical appraisal of existing cost-utility methodology and quality is important to inform future cost-utility analyses of CGM in type 1 diabetes in various settings.Keywords
This publication has 22 references indexed in Scilit:
- Rayyan—a web and mobile app for systematic reviewsSystematic Reviews, 2016
- How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3)Expert Review of Pharmacoeconomics & Outcomes Research, 2016
- How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3)Expert Review of Pharmacoeconomics & Outcomes Research, 2016
- De-duplication of database search results for systematic reviews in EndNoteJournal of the Medical Library Association, 2016
- Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerPharmacoEconomics, 2016
- AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model UsersPharmacoEconomics, 2015
- A protocol for a systematic review of the diagnostic accuracy of blood markers, synovial fluid, and tissue testing in periprosthetic joint infections (PJI)Systematic Reviews, 2015
- Continuous glucose monitoring: A review of biochemical perspectives and clinical use in type 1 diabetesClinical Biochemistry, 2009
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic CriteriaInternational Journal of Technology Assessment in Health Care, 2005